ILDR2 Recombinant Monoclonal Antibody

ILDR2, or immunoglobulin-like domain-containing receptor 2, has emerged as a molecule of considerable interest in immunology research, particularly for its role as a potential immune checkpoint regulator. Studies suggest ILDR2 may function in modulating T cell responses, positioning it as a relevant target for researchers investigating immune regulation, tolerance mechanisms, and potential therapeutic interventions in autoimmune conditions and cancer immunology.

This recombinant monoclonal antibody, clone 13G7, offers the reproducibility and consistency that demanding experimental workflows require. Generated against recombinant human ILDR2 protein and produced using recombinant technology, this antibody provides sequence-defined specificity with minimal lot-to-lot variation. The human IgG1 isotype format and affinity-chromatography purification ensure reliable performance across your experimental timeline.

Validation studies demonstrate this antibody's utility across multiple detection platforms. Immunofluorescence staining has been successfully performed in both HeLa and U251 cell lines at dilutions of 1:30, revealing clear cellular localization patterns when counter-stained with DAPI. For flow cytometry applications, the antibody has been validated using Jurkat cells, a T lymphocyte line particularly relevant for ILDR2's proposed immunological functions. The overlay histogram analysis shows distinct positive signal separation from isotype control, confirming specific detection in this suspension cell format.

The antibody is supplied in a stabilized liquid formulation containing 50% glycerol in PBS at pH 7.4, ready for immediate use without reconstitution. Whether you are characterizing ILDR2 expression patterns in immune cell populations, investigating its role in cellular signaling, or exploring its potential as an immunomodulatory target, this antibody provides the validated performance needed for meaningful experimental outcomes.